22. Orilissa


Active ingredient: elagolix 
Disease: endometriosis 
Peak sales estimate: $2 billion 
Approved: July 24 
Company: AbbVie and Neurocrine Biosciences

The scoop: AbbVie is preparing for a future after biosimilars bite into top-seller Humira, and Orilissa is a big part of it. Execs are expecting a hefty contribution from the therapy, which this summer became the first oral drug to snag an FDA green light for endometriosis in more than a decade. Approval for two dosage strengths will help toward that goal, as will a lack of black-box safety warnings or monitoring requirements for bone mineral density changes, Goldman Sachs analyst Jami Rubin wrote at the time. AbbVie isn’t stopping with endometriosis, though. In November, Orilissa topped placebo in a pair of phase 3 trials at reducing heavy menstrual bleeding related to uterine fibroids, and AbbVie, along with partner Neurocrine Biosciences, expects to file for FDA approval in the middle of 2019. — Carly Helfand 

22. Orilissa

Suggested Articles

In this week's EuroBiotech Report, AstraZeneca plans 2020 lupus filing, Roche's SMA trial hits endpoint and Kiadis cuts staff in R&D pivot.

In our EuroBiotech roundup this week, NEC and Vaximm ink cancer vaccine pact, Compugen posts cancer data and Lunac raises cash.

Biotech venture fund ATAI Life Sciences has partnered with artificial intelligence drug discovery specialist Cyclica to form a new JV.